lorviqua
pfizer europe ma eeig - lorlatinib - carcinoom, niet-kleincellige long - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.
orserdu
stemline therapeutics b.v. - elacestrant - neoplasmata van de borst - endocriene therapie - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.
erlotinib eg 25 mg filmomh. tabl.
eg sa-nv - erlotinibhydrochloride 27,32 mg - eq. erlotinib 25 mg - filmomhulde tablet - 25 mg - erlotinibhydrochloride 27.32 mg - erlotinib
erlotinib eg 50 mg filmomh. tabl.
eg sa-nv - erlotinibhydrochloride 54,63 mg - eq. erlotinib 50 mg - filmomhulde tablet - 50 mg - erlotinibhydrochloride 54.63 mg - erlotinib
erlotinib eg 100 mg filmomh. tabl.
eg sa-nv - erlotinibhydrochloride 109,27 mg - eq. erlotinib 100 mg - filmomhulde tablet - 100 mg - erlotinibhydrochloride 109.27 mg - erlotinib
erlotinib eg 150 mg filmomh. tabl.
eg sa-nv - erlotinibhydrochloride 163,9 mg - eq. erlotinib 150 mg - filmomhulde tablet - 150 mg - erlotinibhydrochloride 163.9 mg - erlotinib
erlotinib sandoz 25 mg filmomh. tabl.
sandoz sa-nv - erlotinibhydrochloride 27,32 mg - eq. erlotinib 25 mg - filmomhulde tablet - 25 mg - erlotinibhydrochloride 27.32 mg - erlotinib
erlotinib sandoz 100 mg filmomh. tabl.
sandoz sa-nv - erlotinibhydrochloride 109,27 mg - eq. erlotinib 100 mg - filmomhulde tablet - 100 mg - erlotinibhydrochloride 109.27 mg - erlotinib
erlotinib sandoz 150 mg filmomh. tabl.
sandoz sa-nv - erlotinibhydrochloride 163,9 mg - eq. erlotinib 150 mg - filmomhulde tablet - 150 mg - erlotinibhydrochloride 163.9 mg - erlotinib
erlotinib apotex 100 mg, filmomhulde tabletten
apotex europe bv archimedesweg 2 2333 cn leiden - erlotinibhydrochloride samenstelling overeenkomend met ; erlotinib - filmomhulde tablet - cellulose, microkristallijn (e 460) ; croscarmellose natrium (e 468) ; hyprolose (e 463) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; lactose 0-water ; magnesiumstearaat (e 470b) ; siliciumdioxide (e 551) ; titaandioxide (e 171) ; triethylcitraat (e 1505), - erlotinib